SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility following a late-evening presidential address that failed to signal a de-escalation in Iran, effectively unwinding the optimism that fueled recent market gains. The investor community is actively debating the reliability of ceasefire rumors and expressing concern over the implications of a prolonged conflict, leading to widespread uncertainty heading into the long holiday weekend.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors react to a high-stakes, prime-time address where the administration outlined its ongoing military strategy in the Middle East. The community remains deeply divided, with intense debate occurring over the economic fallout of the conflict, the presidents erratic messaging, and the broader implications for U.S. foreign policy.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing investor attention as the semiconductor sector rebounds from recent geopolitical volatility, with the community actively debating the stock's resilience amid broader concerns about market manipulation and upcoming high-profile policy announcements. Market participants are split between bullish sentiment fueled by aggressive AI infrastructure spending and bearish skepticism regarding the stock's ability to maintain gains in the face of ongoing macroeconomic uncertainty.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing heightened volatility as investors weigh the implications of an upcoming presidential address regarding the conflict in Iran. Market participants are actively debating whether the administration's rhetoric signals a move toward de-escalation or a potential intensification of military involvement, fueling uncertainty across equity and energy markets.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

Market sentiment for the DIA remains heavily pressured as investors grapple with escalating geopolitical instability in the Middle East and concerns over persistent energy inflation. The community is actively debating the credibility of recent peace talk reports versus the threat of further conflict, leading to widespread volatility and skepticism regarding potential short-term recoveries.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors weigh an upcoming delivery report against broader geopolitical tensions and market volatility following recent executive announcements. Community discussion is sharply divided between those banking on a delivery beat to drive a rebound and skeptics who are wary of valuation concerns and the company's long-term competitive positioning.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as investors react to a significant strategic move to repurchase full control of its Fab 34 facility in Ireland for over $14 billion, a deal aimed at bolstering its manufacturing capacity and long-term foundry competitiveness. While the stock saw a positive reaction to the news, market participants are actively debating the move's impact on Intel's balance sheet, its potential to secure future high-value customers, and broader volatility driven by geopolitical tensions in the Middle East.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing a volatile recovery as investors pivot between speculative war-related macro concerns and bullish enthusiasm regarding sold-out memory capacity and AI-driven supply demand. The community is sharply divided, with bulls pointing to strong fundamental demand and institutional call-buying, while bears remain skeptical of recent price action and persistent geopolitical instability.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is trending following a strategic decision to sell approximately 15,133 BTC to repurchase $1 billion in convertible debt, a move aimed at reducing interest obligations and strengthening the balance sheet. While some market participants praise this as a pragmatic step toward financial discipline and operational agility, the community remains heavily divided, with critics slamming management for selling assets at current price levels and questioning the company's long-term pivot toward AI and high-performance computing infrastructure.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense bearish pressure following a weak earnings outlook and concerns over declining demand in key markets like China, fueling significant community debate over whether the stock is a value trap or a long-term bargain. Investors are actively discussing the company's dividend stability, management performance, and the potential impact of ongoing tariff tensions, with many tracking key support levels while attempting to time a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI and Biotech Enter a Stock Picker’s Market

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...

Why Is Lantern Pharma Stock Soaring Monday?

Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.read more...

<ul class="summary-bullets"><li>PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation.</li><li>Iterum Therapeutics announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.</li><li>Lantern Pharma said the FDA cleared its Investigational New Drug application for STAR-001, a targeted therapy for relapsed or refractory CNS cancers.</li></ul>U.S. equities were in the green in Monday’s pre-market trade amid the ongoing tensions in the Middle East, with President Donald Trump stating on Sunday that Iran had agreed to the 15-point ceasefire plan “for the most part.”At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.49%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.42%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.47%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ELAB">PMGC Holdings Inc. (ELAB)</a>PMGC Holdings shares soared more than 66% in Monday’s pre-market session. The company announced on Friday that its wholly-owned subsidiary, NorthStrive Biosciences, has amended its existing agreement with MOA Life Plus for human clinical trials of its lead candidate EL-22, as well as EL-32, to study the preservation of muscle and lean mass.<a href="https://stocktwits.com/symbol/ELAB">ELAB stock</a> is down 95% year-to-date.<a href="https://stocktwits.com/symbol/ITRM">Iterum Therapeutics PLC (ITRM)</a>Iterum Therapeutics shares more than doubled to soar 110% in Monday’s pre-market trade. The company announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.<a href="https://stocktwits.com/symbol/ITRM">ITRM stock</a> is down 90% year-to-date.<a href="https://stocktwits.com/symbol/LTRN">Lantern Pharma Inc. (LTRN)</a>Lantern Pharma shares gained more than 17% in Monday’s pre-market session. The company announced on Friday that its CEO Panna Sharma continues to serve the Dallas-based biopharmaceutical company. It also announced that the U.S. Food and Drug administration (FDA) cleared its Investigational New Drug (IND) application for STAR-001, its treatment for patients with relapsed or refractory central nervous system (CNS) malignancies.<a href="https://stocktwits.com/symbol/LTRN">LTRN stock</a> is down 63% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bur-stock-sinks-after-us-appeals-court-ruling-argentina-ypf-connection/cZ3HJ4aRIm7">BUR Stock Sinks 40% Following A Reported US Appeals Court Ruling — What Is The Argentina Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Soaring Before The Bell

U.S. equities gained in Monday’s pre-market trade after President Donald Trump stated that Iran had agreed to the 15-point proposal for the most part.

Equity

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AIdriven, clinicalstage oncology company leveraging its proprietary RADR platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on...

Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001

(RTTNews) - Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

<ul class="summary-bullets"><li>STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform.</li><li>The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone.</li><li>The trial to be conducted with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.</li></ul>Shares of Lantern Pharma Inc. (LTRN) surged nearly 18% in pre-market trading on Friday after the biotech firm said that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers.STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform, which helped identify its potential in CNS and pediatric CNS indications, the company said. The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone in children with relapsed or refractory CNS cancers.The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.<h2 class="st-heading-2">Lantern's Drug To Treat Soft Tissue Sarcomas</h2>Earlier this year, the FDA granted Orphan Drug Designation to Lantern Pharma's experimental drug LP-284 for the treatment of soft tissue sarcomas. It marked the third orphan designation for LP-284 and the sixth across the company’s pipeline.Orphan designation provides incentives to support the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S.LP-284 is a small-molecule therapy designed to target cancer cells with DNA repair defects. The drug has shown encouraging activity in early studies, including a complete response in a heavily pretreated lymphoma patient in a Phase 1 trial.The therapy is currently being tested in patients with B-cell non-Hodgkin lymphomas.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/LTRN">LTRN</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/LTRN_jpg_fb27c74f09.webp" alt="LTRN.jpg">The stock has been under heavy selling pressure, slumping more than 50% in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

LTRN Stock Gains 18% Pre-Market: FDA Greenlights First Pediatric Cancer Trial For Oncology Compound

The U.S. Food and Drug Administration cleared its Investigational New Drug application for Lantern Pharma’s oncology compound, paving the way for a Phase 1 clinical trial.

Why Did LTRN Stock Surge 18% In Pre-Market Today? 

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the...

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...

$LTRN Q4 &#39;25 Earnings Results &amp; Recap

Lantern Pharma expects existing cash, cash equivalents, and marketable securities to fund operations until late July to mid-September 2026, requiring substantial additional funding in the near future.

Stocktwits

Lantern Pharma Inc

 Q4 '25 Earnings Results & Recap

Lantern Pharma expects existing cash, cash equivalents, and marketable securities to fund operations until late July to mid-September 2026, requiring substantial additional funding in the near future.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.36	--	--	N/A
Q4 '25	-$0.46	-$0.36	21.74%	BEAT
Q3 '25	-$0.47	-$0.39	17.02%	BEAT
Q2 '25	-$0.44	-$0.40	9.09%	BEAT
Q1 '25	-$0.49	-$0.42	14.29%	BEAT

LTRN
Lantern Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest LTRN News

LTRNLantern Pharma Inc